The must-have medical text, ACSM’s Guidelines for Exercise Testing and Prescription, is back this year with content updates that make the book even more vital for physicians and clinicians. Updates include the addition of "risk classifications," and places a greater emphasis on individualization. The Ninth Edition also contains an abundance of charts and graphs, providing easy access to the information exercise professionals need. In this presentation we discuss these and other changes that make the Ninth Edition of ACSM’s Guidelines for Exercise Testing and Prescription the best yet.
2. ACSM’s Guidelines for Exercise Testing and
Prescription
Prescriptive exercise and exercise testing are highly individualized
practices. The more we know about how both healthy and compromised
bodies work, the better we can fine tune the process of prescribing
exercise, and performing exercise testing.
With this in mind, the completely revised and updated
version of the must-have medical text,
ACSM’s Guidelines for Exercise Testing and Prescription
provides new guidelines on exercise prescription
and testing based on the latest research and
clinical information.
2
3. Charts and Graphs for Quick Reference
The ninth edition of ACSM’s Guidelines for Exercise Testing and
Prescription minimizes prose content and instead includes charts and
graphs to provide fast access to the information clinicians, physicians,
nurses, dietitians and physical therapists need to make appropriate
prescriptive and diagnostic decisions for their patients.
3
4. Prescriptions Based on Risk Classification
The new Guidelines group individuals by low, moderate or high "risk
classifications," as well as by the presence or absence of cardiovascular
disease risk factors, signs and symptoms. This greater emphasis on
individualization allows practitioners to tailor prescriptive advice based
on individual need and ability.
4
5. Emphasis on Special Populations and Needs
This individualized approach to exercise testing and prescriptions is also applied on
a by-condition level. Special sections within ACSM’s Guidelines for Testing and
Prescription provide guidelines for addressing conditions such as:
Cardiovascular disease
Metabolic disease
Pulmonary diseases
Fibromyalgia
Obesity
HIV
Osteoporosis
Intellectual Disabilities
Multiple Sclerosis
And more
5
6. New Chapter on Behavioral Theories and
Strategies
A new 11th chapter discusses strategies for motivating patients based on
behavioral theories, including:
Theoretical strategies and approaches to change
Social theory and self-efficacy
Motivational counseling
Relapse Prevention
And more
A special section provides information on addressing special populations,
including:
Older adults
Children
Individuals with obesity and chronic diseases
Culturally diverse populations
6
7. FITT-VP Boxes Throughout
FITT-VP (Frequency, Intensity Time, Type – Volume) boxes are peppered
throughout the text, providing at-a-glance reference to “best practice”
exercise prescriptions for an individual based upon condition and risk
classification.
7
8. Must-Have Reference for Students and Clinicians
The 9th edition of ACSM’s Guidelines for Testing and Prescription places
emphasis on the physically active lifestyle and provides practitioners and
students alike with the tools they need to help individuals improve their
health by adopting tailored exercise regimens.
For more information, and sample materials, visit the quick reference page
on thepoint.lww.com.
8
9. About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher
of trusted content delivered in innovative ways to practitioners,
professionals and students to learn new skills, stay current on their
practice, and make important decisions to improve patient care and
clinical outcomes. LWW is part of Wolters Kluwer Health, a leading
global provider of information, business intelligence and point-of-care
solutions for the healthcare industry. Wolters Kluwer Health is part
of Wolters Kluwer, a market-leading global information services
company with 2011 annual revenues of €3.4 billion ($4.7 billion).
Source: Trebuchet 10pt regular, left-aligned with slide title
9